SI2468300T1 - Sestavek cepiva, ki vsebuje sintetični adjuvant - Google Patents
Sestavek cepiva, ki vsebuje sintetični adjuvant Download PDFInfo
- Publication number
- SI2468300T1 SI2468300T1 SI200732001T SI200732001T SI2468300T1 SI 2468300 T1 SI2468300 T1 SI 2468300T1 SI 200732001 T SI200732001 T SI 200732001T SI 200732001 T SI200732001 T SI 200732001T SI 2468300 T1 SI2468300 T1 SI 2468300T1
- Authority
- SI
- Slovenia
- Prior art keywords
- group
- adjuvant
- agonist
- modifier
- gla
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims abstract 9
- 239000000203 mixture Substances 0.000 title claims abstract 6
- 229960005486 vaccine Drugs 0.000 title claims abstract 4
- 239000000427 antigen Substances 0.000 claims abstract 3
- 102000036639 antigens Human genes 0.000 claims abstract 3
- 108091007433 antigens Proteins 0.000 claims abstract 3
- 230000028993 immune response Effects 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 239000003607 modifier Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000003599 detergent Substances 0.000 claims 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 3
- 229930182490 saponin Natural products 0.000 claims 3
- 150000007949 saponins Chemical class 0.000 claims 3
- 241000196324 Embryophyta Species 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims 2
- 229940124669 imidazoquinoline Drugs 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010040721 Flagellin Proteins 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 claims 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 claims 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 claims 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 claims 1
- 108010013639 Peptidoglycan Proteins 0.000 claims 1
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000003705 ribosome Anatomy 0.000 claims 1
- -1 stearyl tyrosine Chemical compound 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000568 immunological adjuvant Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 229940124856 vaccine component Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (4)
- Sestavek cepiva, ki vsebuje sintetični adjuvant PATENTNI ZAHTEVKI1. Farmacevtski sestavek, ki obsega (i) adjuvant glikopiranozillipida (GLA), (ii) epitop, biomolekulo, celico ali tkivo, povezano z alergijo ali astmo, in (iii) farmacevtsko sprejemljiv nosilec ali ekscipient, za uporabo pri metodi za stimulacijo antigen-specifičnega imunskega odziva za zdravljenje alergije ali astme v gostitelju, pri čemer ima GLA formulo:kjer: R1, R3, R5 in R6 pomenijo undecil, R2 in R4 sta tridecil.
- 2. Sestavek za uporabo po zahtevku 1, ki nadalje obsega vsaj eno dodatno komponento, izbrano iz skupine, ki jo sestavljajo: (a) ko-adjuvant; (b) Tollu-podobni receptor (TLR) agaonist; (c) saponin ali saponinski mimetik; (d) olje; (e) imunostimulatomi kompleks, kot je ISCOMATRIX ™; (f) modifikator imidazokinolinskega imunskega odziva; in (g) imunski modifikator z dvojno izvorno zanko (dSLIM);
- 3. Sestavek za uporabo po zahtevku 1 ali 2, ki nadalje obsega vsaj eno dodatno komponento, izbrano iz skupine, ki jo sestavljajo (i) ko-adjuvant, izbran iz skupine, ki jo sestavljajo galun, rastlinski alkaloid in detergent, pri čemer je rastlinski alkaloid izbran izmed tomatina in detergent je izbran izmed saponina, polisorbata 80, spana 85 in Stearil tirozina; (ii) agonist TLR je izbran iz skupine, ki jo sestavljajo lipopolisaharid, peptidoglikan, polihC, CpG, 3M003, flagelin, Leishmania homolog evkariotske ribosomske elongacije in iniciacijski faktor 4a (LeIF) in vsaj en hepatitis C antigen; (iii) modifikator imidazokinolinskega imunskega odziva, izbranega iz skupine, ki jo sestavljajo resikvimod (R848), imikvimod in gardikvimod; (iv) ko-adjuvant, izbran iz skupine, ki jo sestavljajo citokin, detergent in blok kopolimer ali biološko razgradljiv polimer; in (v) nosilec, izbran iz skupine, ki jo sestavljajo kalcijev fosfat, emulzija olje-v-vodi, emulzija voda-v-olju, liposom in mikrodelec.
- 4. Sestavek za uporabo po zahtevku 3, kjer je TLR agonist TLR7 agonist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84740406P | 2006-09-26 | 2006-09-26 | |
EP12153267.5A EP2468300B1 (en) | 2006-09-26 | 2007-09-26 | Vaccine composition containing synthetic adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2468300T1 true SI2468300T1 (sl) | 2018-03-30 |
Family
ID=39776582
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200730970T SI2068918T1 (sl) | 2006-09-26 | 2007-09-26 | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
SI200732032T SI2486938T1 (sl) | 2006-09-26 | 2007-09-26 | Sestavek cepiva, ki vsebuje sintetični adjuvans |
SI200732037T SI2484375T1 (sl) | 2006-09-26 | 2007-09-26 | Sestavek za cepljenje, ki vsebuje sintetični adjuvant |
SI200732001T SI2468300T1 (sl) | 2006-09-26 | 2007-09-26 | Sestavek cepiva, ki vsebuje sintetični adjuvant |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200730970T SI2068918T1 (sl) | 2006-09-26 | 2007-09-26 | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
SI200732032T SI2486938T1 (sl) | 2006-09-26 | 2007-09-26 | Sestavek cepiva, ki vsebuje sintetični adjuvans |
SI200732037T SI2484375T1 (sl) | 2006-09-26 | 2007-09-26 | Sestavek za cepljenje, ki vsebuje sintetični adjuvant |
Country Status (20)
Country | Link |
---|---|
US (10) | US8273361B2 (sl) |
EP (6) | EP2468300B1 (sl) |
JP (6) | JP5443164B2 (sl) |
KR (1) | KR101378872B1 (sl) |
CN (2) | CN101516396B (sl) |
AT (1) | ATE555808T1 (sl) |
AU (1) | AU2007354917B2 (sl) |
BR (1) | BRPI0716959A2 (sl) |
CA (1) | CA2662921C (sl) |
CY (4) | CY1112943T1 (sl) |
DK (4) | DK2486938T3 (sl) |
ES (5) | ES2387327T3 (sl) |
HK (1) | HK1132934A1 (sl) |
HU (3) | HUE036180T2 (sl) |
LT (3) | LT2484375T (sl) |
PL (4) | PL2468300T3 (sl) |
PT (4) | PT2486938T (sl) |
SI (4) | SI2068918T1 (sl) |
TR (2) | TR201807756T4 (sl) |
WO (1) | WO2008153541A1 (sl) |
Families Citing this family (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CN1918293A (zh) * | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子 |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
SI2068918T1 (sl) * | 2006-09-26 | 2012-09-28 | Infectious Disease Res Inst | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
US20110245323A1 (en) * | 2006-10-16 | 2011-10-06 | Yale University | RIG-Like Helicase Innate Immunity Inhibits VEGF-Induced Tissue Responses |
MX2009010800A (es) * | 2007-04-04 | 2010-01-29 | Infectious Disease Res Inst Id | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
EP2280720B1 (en) | 2008-03-27 | 2019-01-16 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
US8410258B2 (en) | 2008-05-21 | 2013-04-02 | Infections Disease Research Institute | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis |
US8425919B2 (en) * | 2008-05-21 | 2013-04-23 | Infectious Disease Research Institute | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis |
ES2761697T3 (es) * | 2008-08-28 | 2020-05-20 | Novartis Ag | Proceso para preparar una emulsión de aceite en agua que contiene escualeno procedente de levaduras |
WO2010033812A1 (en) * | 2008-09-18 | 2010-03-25 | Variation Biotechnologies, Inc. | Compositions and methods for treating hepatitis a. |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
EP2376107B1 (en) | 2008-12-09 | 2014-05-21 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
WO2010091265A1 (en) * | 2009-02-05 | 2010-08-12 | Yale University | Compounds and methods for treating viral encephalitis |
EP2437753B1 (en) | 2009-06-05 | 2016-08-31 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
US20110014228A1 (en) * | 2009-06-15 | 2011-01-20 | New York University | Il23 modified viral vector for recombinant vaccines and tumor treatment |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
MX2012000372A (es) * | 2009-07-06 | 2012-02-28 | Variation Biotechnologies Inc | Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas. |
TR201819229T4 (tr) | 2009-07-24 | 2019-01-21 | Immune Design Corp | Entegre olmayan lentiviral vektörler. |
EP2461679B1 (en) | 2009-07-28 | 2019-02-13 | GE Healthcare Bio-Sciences Corp. | Vaccine stabilizer |
US9259476B2 (en) | 2009-07-31 | 2016-02-16 | Wayne State University | Monophosphorylated lipid A derivatives |
US8809285B2 (en) | 2009-07-31 | 2014-08-19 | Wayne State University | Monophosphorylated lipid A derivatives |
PT2525815E (pt) * | 2010-01-24 | 2015-03-05 | Novartis Ag | Micropartículas de polímero biodegradável irradiadas |
BR112012022939A2 (pt) * | 2010-03-11 | 2016-08-02 | Immune Design Corp | composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza |
CA2798074A1 (en) | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Immunogenic compositions and methods for treating neoplasia |
CN101850117B (zh) * | 2010-06-03 | 2012-05-30 | 国家兽用生物制品工程技术研究中心 | 一种复方免疫佐剂及疫苗 |
CA2803167A1 (en) * | 2010-06-23 | 2011-12-29 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans for use in vascular intervention |
US9610248B2 (en) * | 2010-07-06 | 2017-04-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
EP2637687B1 (en) | 2010-11-08 | 2021-01-06 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
CN103501811B (zh) | 2011-01-13 | 2016-03-30 | 变异生物技术公司 | 用于治疗病毒感染的组合物和方法 |
US20120263754A1 (en) * | 2011-02-15 | 2012-10-18 | Immune Design Corp. | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines |
EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
KR101376675B1 (ko) * | 2011-04-19 | 2014-03-20 | 광주과학기술원 | 이미징 및 운반 이중기능 나노입자-기반 백신 전달체 |
US20120288515A1 (en) * | 2011-04-27 | 2012-11-15 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
CN103533953A (zh) * | 2011-05-17 | 2014-01-22 | 葛兰素史密丝克莱恩生物有限公司 | 针对肺炎链球菌的疫苗 |
WO2012162534A2 (en) | 2011-05-24 | 2012-11-29 | Purdue Research Foundation | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use |
ES2936312T3 (es) | 2011-08-31 | 2023-03-16 | Perosphere Tech Inc | Métodos para la desensibilización eficaz y rápida de pacientes alérgicos |
WO2013038185A1 (en) | 2011-09-12 | 2013-03-21 | Jonathan Norden Weber | Methods and compositions for raising an immune response to hiv |
WO2013072768A2 (en) | 2011-11-18 | 2013-05-23 | Variation Biotechnologies, Inc. | Synthetic derivatives of mpl and uses thereof |
AU2013208693B2 (en) | 2012-01-12 | 2017-12-07 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
CN110339160A (zh) * | 2012-02-07 | 2019-10-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
EP2822599A4 (en) * | 2012-03-05 | 2015-12-23 | Univ Duke | VACCINE |
NZ700340A (en) | 2012-03-30 | 2017-02-24 | Immune Design Corp | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
MX350274B (es) * | 2012-05-16 | 2017-08-31 | Immune Design Corp | Vacunas para hsv-2. |
US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
JP2015525784A (ja) * | 2012-08-03 | 2015-09-07 | インフェクティアス ディジーズ リサーチ インスティチュート | 活動性結核菌感染を治療するための組成物及び方法 |
CN103768604B (zh) * | 2012-10-24 | 2016-03-30 | 北京圣沃德生物科技有限公司 | 治疗性肿瘤疫苗 |
ES2819234T3 (es) * | 2013-02-25 | 2021-04-15 | Particle Sciences Inc | Formulaciones de partículas para la administración de agonistas de TLR y antígenos |
MX2015012608A (es) | 2013-03-15 | 2016-07-06 | Symic Biomedical Inc | Peptidos sinteticos de union a matriz extracelular. |
BR112015024860B1 (pt) | 2013-03-28 | 2023-11-07 | Access To Advanced Health Institute | Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica |
BR112015025709A2 (pt) * | 2013-04-18 | 2017-07-18 | Immune Design Corp | monoterapia com gla para uso em tratamento de câncer |
US9463198B2 (en) * | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
JP6697384B2 (ja) | 2013-07-25 | 2020-05-20 | イグジキュア, インコーポレーテッドExicure, Inc. | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 |
WO2015035010A1 (en) * | 2013-09-05 | 2015-03-12 | Immune Design Corp. | Vaccine compositions for drug addiction |
US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
CN106163551A (zh) * | 2013-12-31 | 2016-11-23 | 传染性疾病研究院 | 单瓶疫苗制剂 |
EP3092246B1 (en) | 2014-01-09 | 2019-06-05 | Valneva Austria GmbH | Mutant fragments of ospa and methods and uses relating thereto |
WO2015112485A1 (en) | 2014-01-21 | 2015-07-30 | Immune Design Corp. | Compositions for use in the treatment of allergic conditions |
ES2738582T3 (es) | 2014-02-14 | 2020-01-23 | Immune Design Corp | Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica |
US10772931B2 (en) | 2014-04-25 | 2020-09-15 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
US10111948B2 (en) | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
ES2856834T3 (es) * | 2014-08-04 | 2021-09-28 | Oncotherapy Science Inc | Péptido derivado de URLC10 y vacuna que contiene el mismo |
CN109069618A (zh) * | 2014-09-02 | 2018-12-21 | 卡迪拉保健有限公司 | 免疫刺激性重构流感病毒体与免疫增强剂的协同组合物及包含其的疫苗 |
WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
WO2016149417A1 (en) * | 2015-03-17 | 2016-09-22 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
EP3069729A1 (en) | 2015-03-17 | 2016-09-21 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
TW201709926A (zh) * | 2015-04-23 | 2017-03-16 | 賽諾菲公司 | 用於舌下投藥之吡喃葡萄糖基脂a及過敏原調配物 |
CN113637040A (zh) * | 2015-08-19 | 2021-11-12 | 哈佛学院院长及董事 | 脂化psa组合物和方法 |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
CA2997749A1 (en) | 2015-09-09 | 2017-03-16 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
WO2017083356A1 (en) | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
AU2016354000A1 (en) | 2015-11-09 | 2018-05-17 | Immune Design Corp. | Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof |
BR112018015255A2 (pt) | 2016-02-15 | 2018-12-18 | Hipra Scientific, S.L.U. | extrato de streptococcus uberis como um agente imunogênico |
JP2019509275A (ja) | 2016-02-23 | 2019-04-04 | イミューン デザイン コーポレイション | マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム |
CN105749275A (zh) * | 2016-03-30 | 2016-07-13 | 山东农业大学 | 一种核酸缓释佐剂及其制备和使用方法 |
WO2017200957A1 (en) * | 2016-05-16 | 2017-11-23 | Infectious Disease Research Institute | Pegylated liposomes and methods of use |
EP3458088A2 (en) | 2016-05-21 | 2019-03-27 | Infectious Disease Research Institute | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections |
CA3030974A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
MX2019003035A (es) | 2016-09-16 | 2019-09-13 | Infectious Disease Res Inst | Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra. |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
CA3045952A1 (en) | 2016-12-07 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Novel process |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
EA038864B1 (ru) * | 2016-12-26 | 2021-10-29 | Могам Инститьют Фор Байомедикал Рисерч | Вакцинная композиция против опоясывающего герпеса |
WO2018148180A2 (en) | 2017-02-07 | 2018-08-16 | Immune Design Corp. | Materials and methods for identifying and treating cancer patients |
KR101996538B1 (ko) * | 2017-02-13 | 2019-07-04 | 단디바이오사이언스 주식회사 | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 |
EP3615061A1 (en) | 2017-04-28 | 2020-03-04 | GlaxoSmithKline Biologicals S.A. | Vaccination |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
IE20190086A1 (en) | 2017-05-30 | 2019-12-25 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
CN111315362A (zh) | 2017-06-15 | 2020-06-19 | 传染病研究所 | 纳米结构脂质载剂和稳定乳剂以及其用途 |
KR20200026263A (ko) | 2017-07-07 | 2020-03-10 | 시믹 아이피, 엘엘씨 | 합성 생체접합체 |
CN110169717A (zh) | 2017-08-09 | 2019-08-27 | 沙克忍者运营有限责任公司 | 烹饪系统 |
US20200276299A1 (en) * | 2017-09-08 | 2020-09-03 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
WO2019106192A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
MX2020008417A (es) | 2018-02-12 | 2020-11-11 | Inimmune Corp | Ligandos de receptores de tipo toll. |
MX2021001129A (es) | 2018-07-31 | 2021-07-02 | Glaxosmithkline Biologicals Sa | Metodo de purificacion de antigenos. |
WO2020038298A1 (zh) * | 2018-08-20 | 2020-02-27 | 中国科学院过程工程研究所 | 一种基于微囊的疫苗 |
WO2020059895A1 (ko) * | 2018-09-17 | 2020-03-26 | 주식회사 큐라티스 | 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물 |
US20220339282A1 (en) | 2018-11-29 | 2022-10-27 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
CN109652384B (zh) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
CN109701011B (zh) * | 2019-02-26 | 2022-04-05 | 苏文全 | 疫苗复合佐剂系统及其在抗原中的应用 |
EP3980044A1 (en) | 2019-06-05 | 2022-04-13 | GlaxoSmithKline Biologicals SA | Saponin purification |
WO2020247851A1 (en) * | 2019-06-05 | 2020-12-10 | Global Health Solutions Llc | Transdermal vaccine delivery |
US11911463B2 (en) | 2019-07-16 | 2024-02-27 | Michael J. Dochniak | Topical hyper-allergenic composition and method of treating using the same |
EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
JP2022547298A (ja) | 2019-09-09 | 2022-11-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫療法組成物 |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
EP4038091A1 (en) | 2019-10-02 | 2022-08-10 | Janssen Vaccines & Prevention B.V. | Staphylococcus peptides and methods of use |
RU2724896C1 (ru) * | 2019-11-14 | 2020-06-26 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Полиантигенная вакцина для профилактики и вспомогательного лечения туберкулеза |
US20220387614A1 (en) | 2019-11-22 | 2022-12-08 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
WO2021122551A1 (en) | 2019-12-19 | 2021-06-24 | Glaxosmithkline Biologicals Sa | S. aureus antigens and compositions thereof |
KR20210117832A (ko) * | 2020-03-20 | 2021-09-29 | 강원대학교산학협력단 | Gla-se를 포함하는 수족구병 백신 조성물 |
EP4126021A1 (en) | 2020-03-23 | 2023-02-08 | HDT Bio Corp. | Compositions and methods for delivery of rna |
US11678765B2 (en) | 2020-03-30 | 2023-06-20 | Sharkninja Operating Llc | Cooking device and components thereof |
WO2021224205A1 (en) | 2020-05-05 | 2021-11-11 | Glaxosmithkline Biologicals Sa | Microfluidic mixing device and methods of use |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US20230287038A1 (en) | 2020-08-07 | 2023-09-14 | Access To Advanced Health Institute | Purified saponins and chromatographic process for purification of same |
EP4199961A4 (en) * | 2020-08-20 | 2024-03-13 | Univ Texas | COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER |
WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
US20240026407A1 (en) | 2020-12-09 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Modification of saponins |
CN117120087A (zh) | 2020-12-23 | 2023-11-24 | 高级健康研究所 | 茄尼醇疫苗助剂及其制备方法 |
CA3202311A1 (en) | 2020-12-24 | 2022-06-30 | Anne Osbourn | Methods and enzymes for producing quillaic acid derivatives |
WO2022226035A1 (en) * | 2021-04-21 | 2022-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Toll-like receptor agonist-nanoparticle vaccine adjuvant |
CA3219201A1 (en) | 2021-05-06 | 2022-11-10 | Hipra Scientific, S.L.U. | Sars-cov-2 subunit vaccine |
BR112023023098A2 (pt) | 2021-05-06 | 2024-01-30 | Hipra Scient S L U | Vacina de subunidade de sars-cov-2 |
CN113416255A (zh) * | 2021-06-02 | 2021-09-21 | 广西大学 | 一种抗大片形吸虫Cat L1单克隆抗体及其制备方法与应用 |
WO2022256740A1 (en) | 2021-06-04 | 2022-12-08 | Curia Ip Holdings, Llc | Polymeric fusion proteins and compositions for inducing an immune response against infection |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023180677A1 (en) | 2022-03-25 | 2023-09-28 | Plant Bioscience Limited | Biosynthesis |
WO2023242187A1 (en) | 2022-06-15 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Enzymatic modification of saponins |
GB202209588D0 (en) | 2022-06-29 | 2022-08-10 | Plant Bioscience Ltd | Methods and compositions |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1001427A (en) | 1911-05-13 | 1911-08-22 | Walter S Morton | Concrete dam. |
US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4029762A (en) | 1971-11-17 | 1977-06-14 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Lipid A-preparation |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4420558A (en) | 1981-02-12 | 1983-12-13 | Janssen Pharmaceutica N.V. | Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
JPS591527A (ja) | 1982-06-25 | 1984-01-06 | Mitsubishi Monsanto Chem Co | ポリエステルの製造方法 |
US4420461A (en) | 1982-05-26 | 1983-12-13 | Ortho Diagnostic Systems Inc. | Agglutination-inhibition test kit for detecting immune complexes |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
US4743540A (en) | 1983-09-27 | 1988-05-10 | Memorial Sloan-Kettering Cancer Center | Method for diagnosis of subclassifications of common varied immunodeficiency disease group |
US5147785A (en) | 1983-11-01 | 1992-09-15 | Amtl Corporation | Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells |
US4614722A (en) | 1983-11-01 | 1986-09-30 | Pasula Mark J | Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies |
US4595654A (en) | 1983-11-07 | 1986-06-17 | Immunomedics Inc. | Method for detecting immune complexes in serum |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
US4844894A (en) | 1984-07-12 | 1989-07-04 | Ribi Immunochem Research Inc. | Method of inhibiting the onset of septicemia and endotoxemia |
US4629722A (en) | 1984-07-12 | 1986-12-16 | Ribi Immunochem Research, Inc. | Method of inhibiting the onset of acute radiation syndrome |
US5612041A (en) | 1984-07-17 | 1997-03-18 | Chiron Corporation | Recombinant herpes simplex gD vaccine |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4659659A (en) | 1985-01-22 | 1987-04-21 | Monsanto Company | Diagnostic method for diseases having an arthritic component |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4746742A (en) | 1985-11-28 | 1988-05-24 | Toho Yakuhin Kogyo Kabushiki Kaisha | Analogs of nonreducing monosaccharide moiety of lipid A |
US5310651A (en) | 1986-01-22 | 1994-05-10 | Institut Pasteur | DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2 |
US6544728B1 (en) | 1986-01-22 | 2003-04-08 | Institut Pasteur | Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2 |
US6514691B1 (en) | 1986-01-22 | 2003-02-04 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2 |
US6054565A (en) | 1986-03-03 | 2000-04-25 | Institut Pasteur | Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2 |
US5169763A (en) | 1986-04-08 | 1992-12-08 | Transgene S.A., Institut Pasteur | Viral vector coding glycoprotein of HIV-1 |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
JPH0755906B2 (ja) | 1986-07-01 | 1995-06-14 | 第一製薬株式会社 | ジサツカライド誘導体含有鎮痛剤 |
US4948587A (en) | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
FR2672290B1 (fr) | 1991-02-05 | 1995-04-21 | Pasteur Institut | Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t. |
US5565209A (en) | 1987-03-17 | 1996-10-15 | Akzo Nobel N.V. | Adjuvant mixture |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
US4780212A (en) | 1987-07-31 | 1988-10-25 | Massachusetts Institute Of Technology | Ultrasound enchancement of membrane permeability |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
EP0324455A3 (en) | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Novel polymeric immunological adjuvants |
GB2232892B (en) | 1988-02-23 | 1991-07-24 | John Mark Tucker | Occlusive body for administering a physiologically active substance |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5888519A (en) | 1988-06-02 | 1999-03-30 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
DE3826572A1 (de) | 1988-08-04 | 1990-02-08 | Hoechst Ag | Verfahren zur herstellung von hochreinem 5,5'-(2,2,2-trifluor-1-(trifluormethyl) -ethyliden) bis-1,3-isobenzofurandion, verwendung des verfahrensproduktes zur herstellung von polyimiden sowie deren verwendung in der mikroelektronik |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
US5231168A (en) | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
CA2005704C (en) | 1988-12-16 | 2003-02-11 | James C. Paton | Pneumolysin mutants and pneumococcal vaccines made therefrom |
EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
DE69015222T2 (de) | 1989-02-04 | 1995-05-04 | Akzo Nv | Tocole als Impfstoffadjuvans. |
US4886034A (en) | 1989-03-30 | 1989-12-12 | Gas Research Institute | Internal combustion engine control system |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
US5158939A (en) | 1989-07-21 | 1992-10-27 | Wisconsin Alumni Research Foundation | Method of stimulating the immune systems of animals and compositions useful therefor |
SG48175A1 (en) | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US4981684A (en) | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
US6120769A (en) | 1989-11-03 | 2000-09-19 | Immulogic Pharmaceutical Corporation | Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor |
US5298396A (en) | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
US5124141A (en) | 1990-06-14 | 1992-06-23 | Flow Incorporated | Method for diagnosing malaria |
US5162990A (en) | 1990-06-15 | 1992-11-10 | The United States Of America As Represented By The United States Navy | System and method for quantifying macrophage phagocytosis by computer image analysis |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
ES2279020T3 (es) | 1991-07-19 | 2007-08-16 | The University Of Queensland | Vacuna contra el papilomavirus humano. |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
US6197311B1 (en) | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
RO116459B1 (ro) | 1991-07-25 | 2001-02-28 | Idec Pharma Corp | Compozitie imunogena |
AU2143992A (en) | 1991-08-16 | 1993-03-16 | Vical, Inc. | Composition and method for treating cystic fibrosis |
AU660325B2 (en) | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
US5530113A (en) | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
EP0614465B1 (en) | 1991-11-16 | 1999-03-17 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG |
US6057427A (en) | 1991-11-20 | 2000-05-02 | Trustees Of Dartmouth College | Antibody to cytokine response gene 2(CR2) polypeptide |
JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
US5286718A (en) | 1991-12-31 | 1994-02-15 | Ribi Immunochem Research, Inc. | Method and composition for ameliorating tissue damage due to ischemia and reperfusion |
JPH05328975A (ja) | 1992-06-02 | 1993-12-14 | Takara Shuzo Co Ltd | E1a−f遺伝子 |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
PT647140E (pt) | 1992-06-25 | 2007-12-27 | Univ Georgetown | Vacinas de papilomavírus |
UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US5411865A (en) | 1993-01-15 | 1995-05-02 | Iasys Corporation | Method of detecting anti-leishmania parasite antibodies |
EP1588713B1 (en) | 1993-03-09 | 2010-12-22 | The University Of Rochester | Production of human papillomavirus HBV-11 capsid protein L1 and virus-like particles |
ATE204762T1 (de) * | 1993-03-23 | 2001-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
US5532133A (en) | 1993-06-02 | 1996-07-02 | New York University | Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays |
JP3286030B2 (ja) | 1993-08-10 | 2002-05-27 | 株式会社東芝 | 保全管理装置および保全管理ガイド装置 |
US6106824A (en) | 1993-08-13 | 2000-08-22 | The Rockefeller University | Expression of growth associated protein B-50/GAP-43 in vitro and in vivo |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
DE69433695T2 (de) | 1993-11-02 | 2004-08-12 | Matsushita Electric Industrial Co., Ltd., Kadoma | Halbleiterbauelement mit Aggregat von Mikro-Nadeln aus Halbleitermaterial |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
RU2154068C2 (ru) | 1993-11-17 | 2000-08-10 | Лаборатуар Ом С.А. | Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция |
US5693531A (en) | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5457041A (en) | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US7037712B2 (en) | 1994-07-26 | 2006-05-02 | Commonwealth Scientific And Industrial Research Organisation | DNA encoding ovine adenovirus (OAV287) and its use as a viral vector |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
SE9403137D0 (sv) | 1994-09-20 | 1994-09-20 | Perstorp Ab | Derivatives of carbohydrates and compositions containing them |
EP1728800A1 (de) | 1994-10-07 | 2006-12-06 | Loyola University Of Chicago | Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
DE69633272T2 (de) | 1995-02-08 | 2005-09-08 | Takara Bio Inc., Otsu | Methoden zur Krebsbehandlung und -kontrolle |
WO1996026277A1 (en) | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
US5912166A (en) | 1995-04-21 | 1999-06-15 | Corixa Corporation | Compounds and methods for diagnosis of leishmaniasis |
US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US5718904A (en) | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
US6417172B1 (en) | 1995-06-05 | 2002-07-09 | Eisai Co., Ltd. | Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
US5993800A (en) | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US5631245A (en) * | 1995-06-06 | 1997-05-20 | Biodynamics Pharmaceuticals, Inc. | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions |
US6309847B1 (en) | 1995-07-05 | 2001-10-30 | Yeda Research And Development Co. Ltd. | Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
WO1997011708A1 (en) | 1995-09-29 | 1997-04-03 | Eisai Research Institute | Method for treating alcoholic liver disease |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5618275A (en) | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5846758A (en) | 1995-11-30 | 1998-12-08 | His Excellency Ghassan I. Shaker | Method for diagnosing autoimmune diseases |
US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
SE9600648D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Receptorbimdande enhet |
US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
ES2242226T3 (es) | 1996-07-03 | 2005-11-01 | Eisai Co., Ltd. | Composiciones que contienen analogos del lipido a y procedimiento parasu preparacion. |
ATE229073T1 (de) | 1996-09-06 | 2002-12-15 | Univ California | Protein e25a, methoden zu dessen herstellung und anwendung |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
JPH10131046A (ja) | 1996-10-29 | 1998-05-19 | Nikka Chem Co Ltd | 繊維の耐久性pH緩衝加工方法 |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US7033598B2 (en) | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
DE19654221B4 (de) | 1996-12-23 | 2005-11-24 | Telefonaktiebolaget Lm Ericsson (Publ) | Leitungsanschlußschaltkreis |
US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
US6977073B1 (en) | 1997-02-07 | 2005-12-20 | Cem Cezayirli | Method for stimulating an immune response |
WO2000004149A2 (en) | 1998-07-14 | 2000-01-27 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
DE69831222T2 (de) | 1997-02-25 | 2006-07-13 | Corixa Corp., Seattle | Verbindungen zur immundiagnose von prostatakrebs und deren verwendung |
US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
AU743114B2 (en) | 1997-04-01 | 2002-01-17 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid A |
US7037510B2 (en) | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
US6555653B2 (en) | 1997-05-20 | 2003-04-29 | Corixa Corporation | Compounds for diagnosis of tuberculosis and methods for their use |
US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
WO1998058956A2 (en) * | 1997-06-23 | 1998-12-30 | Ludwig Institute For Cancer Research | Methods for inducing an immune response involving prime-boost protocols |
US6764686B2 (en) | 1997-07-21 | 2004-07-20 | Baxter International Inc. | Modified immunogenic pneumolysin compositions as vaccines |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
WO1999010008A1 (en) | 1997-08-29 | 1999-03-04 | Aquila Biopharmaceuticals, Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
US6368604B1 (en) | 1997-09-26 | 2002-04-09 | University Of Maryland Biotechnology Institute | Non-pyrogenic derivatives of lipid A |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
EP2228384A1 (en) | 1997-11-28 | 2010-09-15 | Merck Serono Biodevelopment | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
US7012134B2 (en) | 1998-01-26 | 2006-03-14 | Human Genome Sciences, Inc. | Dendritic enriched secreted lymphocyte activation molecule |
DE19803453A1 (de) | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
BR9907691B1 (pt) | 1998-02-05 | 2011-05-31 | derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. | |
EP0936629B1 (de) | 1998-02-12 | 2006-09-13 | Infineon Technologies AG | EEPROM und Verfahren zur Ansteuerung eines EEPROM |
JP2002502884A (ja) | 1998-02-12 | 2002-01-29 | アメリカン・サイアナミド・カンパニー | インターロイキン−12および単純ヘルペスウイルス抗原を含んでなるワクチン |
US6596501B2 (en) | 1998-02-23 | 2003-07-22 | Fred Hutchinson Cancer Research Center | Method of diagnosing autoimmune disease |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
ATE339223T1 (de) | 1998-03-09 | 2006-10-15 | Glaxosmithkline Biolog Sa | Kombinierte impfstoffzusammensetzungen |
IL138809A0 (en) | 1998-04-07 | 2001-10-31 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same |
GB2336310B (en) | 1998-04-14 | 2003-09-10 | Stowic Resources Ltd | Method of manufacturing transdermal patches |
AU3560399A (en) | 1998-04-15 | 1999-11-01 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
CA2330610A1 (en) | 1998-05-07 | 1999-11-11 | Corixa Corporation | Adjuvant composition and methods for its use |
US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
WO2000013029A1 (fr) | 1998-09-01 | 2000-03-09 | Eisai Co., Ltd | Procede pour evaluer des injections contenant des analogues de lipide a |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
WO2000018929A2 (en) | 1998-09-25 | 2000-04-06 | Smithkline Beecham Biologicals S.A. | Paramyxovirus vaccines |
US6375944B1 (en) | 1998-09-25 | 2002-04-23 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 |
US7001770B1 (en) | 1998-10-15 | 2006-02-21 | Canji, Inc. | Calpain inhibitors and their applications |
KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
US6261573B1 (en) | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
US6512102B1 (en) | 1998-12-31 | 2003-01-28 | Chiron Corporation | Compositions and methods of diagnosis and treatment using casein kinase I |
WO2000042994A2 (en) | 1999-01-21 | 2000-07-27 | North Shore-Long Island Jewish Research Institute | Inhibition of bacterial dissemination |
AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
US20030170249A1 (en) | 1999-02-19 | 2003-09-11 | Hakomori Sen-Itiroh | Vaccines directed to cancer-associated carbohydrate antigens |
US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
WO2000062066A1 (fr) | 1999-04-07 | 2000-10-19 | Hitachi Chemical Co., Ltd. | PROCEDE D'EVALUATION DE MALADIES AUTO-IMMUNES, PROCEDE DE DETECTION D'ANTICORPS DE PROTEINE ANTI-Reg ET DIAGNOSTICS POUR MALADIES AUTO-IMMUNES |
WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
US6685699B1 (en) | 1999-06-09 | 2004-02-03 | Spectrx, Inc. | Self-removing energy absorbing structure for thermal tissue ablation |
EP1206533A1 (en) | 1999-08-26 | 2002-05-22 | Pharmacia AB | Novel response element |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US7084256B2 (en) | 1999-09-24 | 2006-08-01 | Large Scale Biology Corporation | Self antigen vaccines for treating B cell lymphomas and other cancers |
JP4162813B2 (ja) | 1999-10-28 | 2008-10-08 | 久光製薬株式会社 | イオントフォレーシス装置 |
US6218186B1 (en) | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
JP2003514824A (ja) | 1999-11-15 | 2003-04-22 | ビオミラ,インコーポレーテッド | 合成脂質−a類似体およびその使用 |
US20020064801A1 (en) | 1999-12-01 | 2002-05-30 | Ryan Jeffrey R. | Novel and practical serological assay for the clinical diagnosis of leishmaniasis |
US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
US6587792B1 (en) | 2000-01-11 | 2003-07-01 | Richard A. Thomas | Nuclear packing efficiency |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
AU2001233132A1 (en) | 2000-01-31 | 2001-08-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Hybrid adeno-retroviral vector for the transfection of cells |
EP1122542A1 (en) | 2000-02-01 | 2001-08-08 | Anda Biologicals S.A. | Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents |
AU2001241738A1 (en) | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
KR100829674B1 (ko) | 2000-05-19 | 2008-05-16 | 코릭사 코포레이션 | 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법 |
WO2001092550A2 (en) | 2000-05-31 | 2001-12-06 | Human Gene Therapy Research Institute | Methods and compositions for efficient gene transfer using transcomplementary vectors |
DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
US6969704B1 (en) | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
US7060802B1 (en) | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
WO2002028424A2 (en) | 2000-10-06 | 2002-04-11 | Paradies H Henrich | Kyberdrug as autovaccines with immune-regulating effects |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
JP2004511527A (ja) | 2000-10-18 | 2004-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2003004525A2 (en) | 2001-01-26 | 2003-01-16 | Walter Reed Army Institute Of Research | Isolation and purification of plasmodium falciparum merozoite protein-142 |
US6893820B1 (en) | 2001-01-31 | 2005-05-17 | The Ohio State University Research Foundation | Detection of methylated CpG rich sequences diagnostic for malignant cells |
GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
WO2002077195A2 (en) | 2001-03-26 | 2002-10-03 | Walter Reed Army Institute Of Research | Plasmodium falciparum ama-1 protein and uses thereof |
US7029685B2 (en) | 2001-03-26 | 2006-04-18 | The United States Of America As Represented By The Secretary Of The Army | Plasmodium falciparum AMA-1 protein and uses thereof |
US6933123B2 (en) | 2001-04-05 | 2005-08-23 | Yao Xiong Hu | Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers |
US6844192B2 (en) | 2001-06-29 | 2005-01-18 | Wake Forest University | Adenovirus E4 protein variants for virus production |
US7727974B2 (en) | 2001-08-10 | 2010-06-01 | Eisai R & D Management Co., Ltd. | Methods of reducing the severity of mucositis |
WO2003021227A2 (en) | 2001-09-05 | 2003-03-13 | The Children's Hospital Of Philadelphia | Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
US6752995B2 (en) | 2002-04-15 | 2004-06-22 | Board Of Regents, The University Of Texas System | Nucleic acid and polypeptide sequences useful as adjuvants |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
US7820627B2 (en) | 2002-05-09 | 2010-10-26 | Oncothyreon Inc. | Lipid A and other carbohydrate ligand analogs |
US7018345B2 (en) | 2002-12-06 | 2006-03-28 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
TW200416046A (en) * | 2002-12-23 | 2004-09-01 | Alcon Inc | Contact lens care compositions containing chitin derivatives |
US20050123550A1 (en) | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
FR2857875A1 (fr) | 2003-07-25 | 2005-01-28 | Univ Reims Champagne Ardenne | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers |
US20050244419A1 (en) | 2003-07-25 | 2005-11-03 | Pierre-Francois Tosi | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
FR2862062B1 (fr) | 2003-11-06 | 2005-12-23 | Oreal | Lipide a et composition topique, notamment cosmetique, le comprenant |
WO2006055729A1 (en) | 2004-11-16 | 2006-05-26 | Transcutaneous Technologies Inc. | Iontophoretic device and method for administering immune response-enhancing agents and compositions |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
SI2068918T1 (sl) * | 2006-09-26 | 2012-09-28 | Infectious Disease Res Inst | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
EP2437753B1 (en) | 2009-06-05 | 2016-08-31 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
US9241988B2 (en) | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
JP5328975B2 (ja) | 2012-12-19 | 2013-10-30 | ルネサスエレクトロニクス株式会社 | Rfパワーモジュール |
-
2007
- 2007-09-26 SI SI200730970T patent/SI2068918T1/sl unknown
- 2007-09-26 PT PT121532568T patent/PT2486938T/pt unknown
- 2007-09-26 ES ES07875082T patent/ES2387327T3/es active Active
- 2007-09-26 DK DK12153256.8T patent/DK2486938T3/en active
- 2007-09-26 SI SI200732032T patent/SI2486938T1/sl unknown
- 2007-09-26 PT PT07875082T patent/PT2068918E/pt unknown
- 2007-09-26 TR TR2018/07756T patent/TR201807756T4/tr unknown
- 2007-09-26 PL PL12153267T patent/PL2468300T3/pl unknown
- 2007-09-26 ES ES12153249.3T patent/ES2675915T3/es active Active
- 2007-09-26 TR TR2018/09043T patent/TR201809043T4/tr unknown
- 2007-09-26 SI SI200732037T patent/SI2484375T1/sl unknown
- 2007-09-26 DK DK12153267.5T patent/DK2468300T3/da active
- 2007-09-26 SI SI200732001T patent/SI2468300T1/sl unknown
- 2007-09-26 EP EP12153267.5A patent/EP2468300B1/en active Active
- 2007-09-26 LT LTEP12153249.3T patent/LT2484375T/lt unknown
- 2007-09-26 US US11/862,122 patent/US8273361B2/en active Active
- 2007-09-26 HU HUE12153267A patent/HUE036180T2/hu unknown
- 2007-09-26 PL PL12153249T patent/PL2484375T3/pl unknown
- 2007-09-26 ES ES12153267.5T patent/ES2657392T3/es active Active
- 2007-09-26 PT PT121532493T patent/PT2484375T/pt unknown
- 2007-09-26 ES ES12153256.8T patent/ES2673046T3/es active Active
- 2007-09-26 LT LTEP12153267.5T patent/LT2468300T/lt unknown
- 2007-09-26 CN CN2007800357746A patent/CN101516396B/zh active Active
- 2007-09-26 HU HUE12153249A patent/HUE037808T2/hu unknown
- 2007-09-26 CA CA2662921A patent/CA2662921C/en active Active
- 2007-09-26 DK DK12153249.3T patent/DK2484375T3/en active
- 2007-09-26 EP EP18165195.1A patent/EP3403667B1/en active Active
- 2007-09-26 EP EP12153256.8A patent/EP2486938B1/en active Active
- 2007-09-26 PL PL12153256T patent/PL2486938T3/pl unknown
- 2007-09-26 ES ES18165195T patent/ES2822058T3/es active Active
- 2007-09-26 AU AU2007354917A patent/AU2007354917B2/en active Active
- 2007-09-26 AT AT07875082T patent/ATE555808T1/de active
- 2007-09-26 BR BRPI0716959-0A2A patent/BRPI0716959A2/pt not_active Application Discontinuation
- 2007-09-26 DK DK07875082.5T patent/DK2068918T3/da active
- 2007-09-26 HU HUE12153256A patent/HUE037901T2/hu unknown
- 2007-09-26 JP JP2009529280A patent/JP5443164B2/ja active Active
- 2007-09-26 LT LTEP12153256.8T patent/LT2486938T/lt unknown
- 2007-09-26 EP EP20187078.9A patent/EP3795173A1/en active Pending
- 2007-09-26 KR KR1020097008370A patent/KR101378872B1/ko active IP Right Grant
- 2007-09-26 EP EP07875082A patent/EP2068918B1/en active Active
- 2007-09-26 EP EP12153249.3A patent/EP2484375B1/en active Active
- 2007-09-26 PT PT121532675T patent/PT2468300T/pt unknown
- 2007-09-26 CN CN201310404297.3A patent/CN103705919B/zh active Active
- 2007-09-26 PL PL07875082T patent/PL2068918T3/pl unknown
- 2007-09-26 WO PCT/US2007/021017 patent/WO2008153541A1/en active Application Filing
-
2009
- 2009-12-15 HK HK09111743.8A patent/HK1132934A1/xx unknown
-
2012
- 2012-07-26 CY CY20121100668T patent/CY1112943T1/el unknown
- 2012-08-30 US US13/599,695 patent/US8609114B2/en active Active
- 2012-08-30 US US13/599,701 patent/US8840908B2/en active Active
-
2013
- 2013-06-28 US US13/930,953 patent/US9987355B2/en active Active
- 2013-08-23 JP JP2013172778A patent/JP5778725B2/ja active Active
- 2013-12-04 US US14/096,582 patent/US9907845B2/en active Active
-
2014
- 2014-12-23 US US14/581,062 patent/US9950063B2/en active Active
-
2015
- 2015-07-09 JP JP2015137685A patent/JP2016000738A/ja active Pending
-
2016
- 2016-11-10 JP JP2016219466A patent/JP6190031B2/ja active Active
-
2017
- 2017-08-03 JP JP2017150561A patent/JP6463808B2/ja active Active
- 2017-11-28 US US15/823,852 patent/US10765736B2/en active Active
-
2018
- 2018-01-19 US US15/875,517 patent/US10792359B2/en active Active
- 2018-01-24 CY CY20181100089T patent/CY1119822T1/el unknown
- 2018-06-06 CY CY20181100594T patent/CY1120305T1/el unknown
- 2018-06-12 CY CY20181100609T patent/CY1120328T1/el unknown
-
2019
- 2019-01-04 JP JP2019000232A patent/JP2019070007A/ja active Pending
-
2020
- 2020-04-22 US US16/855,656 patent/US20210069324A1/en not_active Abandoned
- 2020-04-22 US US16/855,622 patent/US20210069323A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2468300T1 (sl) | Sestavek cepiva, ki vsebuje sintetični adjuvant | |
Tan et al. | Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants | |
Duthie et al. | Use of defined TLR ligands as adjuvants within human vaccines | |
Weeratna et al. | CpG DNA induces stronger immune responses with less toxicity than other adjuvants | |
WO2009143457A3 (en) | Vaccine composition containing synthetic adjuvant | |
Mutwiri et al. | Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen | |
Fox et al. | Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines | |
MX2009000660A (es) | Vacuna de influenza. | |
TW200722101A (en) | Novel composition | |
Nkolola et al. | Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer | |
EA201300102A1 (ru) | Лиофилизированная антигенная композиция | |
Coler et al. | Adjuvants for malaria vaccines | |
Gray et al. | Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant | |
Cheng et al. | A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge | |
Yin et al. | Efficacy of modified levamisole adjuvant on inactivated virus vaccine | |
Lastre et al. | Bacterial derived proteoliposome for allergy vaccines | |
PALACPAC et al. | Preclinical studies on a new vaccine formulation of BK-SE36, a malaria vaccine candidate | |
Yu et al. | Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine | |
Qian et al. | Intranasal immunization with a peptide conjugated to Salmonella flagellin induces both systemic and mucosal peptide‐specific antibody responses in mice | |
Flower | Towards the systematic discovery of immunomodulatory adjuvants | |
Schotsaert et al. | Christina Lisk 1, Rachel Yuen 2, Jeff Kuniholm 2, Danielle Antos 3, Michael L. Reiser4 and Lee M. Wetzler 1, 2 | |
Fox et al. | Enhancing and tailoring the immunogenicity of vaccines with novel adjuvants | |
SG139618A1 (en) | Influenza vaccine | |
SG160386A1 (en) | Novel composition |